Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Eustace

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
Cell Death & Disease|July 13, 2026
MARCKS as a mediator and target for pathological tunneling nanotubes between patient-derived glioblastoma cells and astrocytesLauren C Nassour-Caswell, Mayada Ahmed, Shane T Rich-New, et al.
Oncogene|October 20, 2020
A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastomaNicholas J Eustace, Joshua C Anderson, Jason M Warram, et al.
International Journal of Molecular Sciences|October 16, 2025
A Novel Serum-Free Triculture Model of Glioblastoma, Astrocytes, and MacrophagesHasan Alrefai, Lauren C Nassour-Caswell, Manoj Kumar, et al.
Oncogene|December 20, 2025
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patientsCharlotte Andrieu, Jojanneke Stoof, Dalal AlSultan, et al.
Breast Cancer Research and Treatment|November 3, 2012
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumoursBrigid C Browne, Alex J Eustace, Susan Kennedy, et al.
Plos One|March 15, 2023
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancerSandra Roche, Patricia Gaule, Deirdre Winrow, et al.
Therapeutic Advances in Medical Oncology|February 18, 2020
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancerAlexandra Canonici, Alacoque L Browne, Mohamed F K Ibrahim, et al.
Cancer Treatment and Research Communications|April 17, 2025
Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancerAoife Carr, Jonathan A Coulter, Julie Workman, et al.
British Journal of Cancer|July 28, 2023
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapyNicola Gaynor, Alfonso Blanco, Stephen F Madden, et al.
International Journal of Oncology|April 4, 2019
Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastomaNicholas J Eustace, Joshua C Anderson, Catherine P Langford, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
Cell Death & Disease|July 13, 2026
MARCKS as a mediator and target for pathological tunneling nanotubes between patient-derived glioblastoma cells and astrocytesLauren C Nassour-Caswell, Mayada Ahmed, Shane T Rich-New, et al.
Oncogene|October 20, 2020
A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastomaNicholas J Eustace, Joshua C Anderson, Jason M Warram, et al.
International Journal of Molecular Sciences|October 16, 2025
A Novel Serum-Free Triculture Model of Glioblastoma, Astrocytes, and MacrophagesHasan Alrefai, Lauren C Nassour-Caswell, Manoj Kumar, et al.
Oncogene|December 20, 2025
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patientsCharlotte Andrieu, Jojanneke Stoof, Dalal AlSultan, et al.
Breast Cancer Research and Treatment|November 3, 2012
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumoursBrigid C Browne, Alex J Eustace, Susan Kennedy, et al.
Plos One|March 15, 2023
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancerSandra Roche, Patricia Gaule, Deirdre Winrow, et al.
Therapeutic Advances in Medical Oncology|February 18, 2020
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancerAlexandra Canonici, Alacoque L Browne, Mohamed F K Ibrahim, et al.
Cancer Treatment and Research Communications|April 17, 2025
Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancerAoife Carr, Jonathan A Coulter, Julie Workman, et al.
British Journal of Cancer|July 28, 2023
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapyNicola Gaynor, Alfonso Blanco, Stephen F Madden, et al.
International Journal of Oncology|April 4, 2019
Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastomaNicholas J Eustace, Joshua C Anderson, Catherine P Langford, et al.
Pageof 13